INBX Inhibrx Biosciences, Inc.
Debt Financing ·
Inhibrx's Oxford Finance facility now totals up to $500.0 million. The company funded $100.0 million at signing, and up to $225.0 million more depends on the lenders' discretion.
A second amendment adds a tranche of up to $325.0 million, of which $100.0 million was funded at signing. The lenders received warrants for 21,457 shares at $93.21 per share.
The loan agreement allows up to $150.0 million, with the remaining $50.0 million at the lenders' sole discretion. The loan matures January 1, 2030 and comes with warrants for 140,741 shares at $14.21. Oxford Finance LLC is collateral agent.
The five-year facility pays interest only until March 2028. Oxford also received warrants for 140,741 shares at $14.21 per share.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates developed using its proprietary modular protein engineering platforms. After a May 2024 separation and merger involving its former parent and a subsidiary of Sanofi, the company continues as a stand-alone, publicly traded company focused on ozekibart (INBRX-109) and INBRX-106, both of which are clinical-stage programs. Ozekibart is a tetravalent therapeutic candidate targeting death receptor 5, or DR5, which the company says induces cancer-specific programmed cell death. It is being investigated in chondrosarcoma, Ewing sarcoma, colorectal cancer and certain other solid tumor types. In October 2025 the company announced positive data from its ozekibart registration-enabling trial in advanced or metastatic, unresectable chondrosarcoma. INBRX-106 is a hexavalent OX40 agonist being investigated in non-small cell lung cancer and head and neck squamous cell carcinoma. The company says both programs have key data or milestone events expected in 2026. Its team brings experience from organizations including Genentech, Gilead Sciences, Merck, Novartis, Pfizer and Roche.
| Product or program | What it is | Stage |
|---|---|---|
| Ozekibart (INBRX-109) | Tetravalent DR5 agonist for chondrosarcoma and other solid tumors | Registration-enabling trial; positive data announced October 2025 |
| INBRX-106 | Hexavalent OX40 agonist for non-small cell lung cancer and head and neck squamous cell carcinoma | Clinical-stage |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.3 million | $200,000 |
| Research and development | $113.0 million | $203.7 million |
| Net income (loss) | -$140.1 million | $1.69 billion |
| Cash from operations | -$129.8 million | -$194.4 million |
| Cash and equivalents | $124.2 million | $152.6 million |
Inhibrx Biosciences, Inc. trades under the ticker INBX on NASDAQ.
Inhibrx Biosciences, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Inhibrx Biosciences, Inc. is 2007919. Its filings are on SEC EDGAR.
14,717,660 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Inhibrx Biosciences, Inc. under United States.
Our directory classifies Inhibrx Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Inhibrx Biosciences, Inc. is US45720N1037.
aibio.space lists Inhibrx Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates developed using its proprietary modular protein engineering platforms. After a May 2024 separation and merger involving its former parent and a subsidiary of Sanofi, the company continues as a stand-alone, publicly traded company focused on ozekibart (INBRX-109) and INBRX-106, both of which are clinical-stage programs.
Ozekibart (INBRX-109): Tetravalent DR5 agonist for chondrosarcoma and other solid tumors Stage: Registration-enabling trial; positive data announced October 2025.
INBRX-106: Hexavalent OX40 agonist for non-small cell lung cancer and head and neck squamous cell carcinoma Stage: Clinical-stage.
$1.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Inhibrx Biosciences, Inc. reported a net loss of $140.1 million for the fiscal year ended Dec 31, 2025, and used $129.8 million of cash in operations, per its annual report to the SEC.
$113.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio